How-pharma-can-overcome-inflation: Difference between revisions
Article published by [[Other sources |Pharma manufacturing]] and reviewed by Nikolay Sidelnikov
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
}}=== Abstract === | }}=== Abstract === | ||
The article [https://www.pharmamanufacturing.com/quality-risk/supply-chain/article/11414874/how-pharma-can-overcome-inflation How pharma can overcome inflation] was published by Pharma manufacturing in 2022. | The article [https://www.pharmamanufacturing.com/quality-risk/supply-chain/article/11414874/how-pharma-can-overcome-inflation How pharma can overcome inflation] was published by Pharma manufacturing in 2022. It describes the potential effect of D2C business model that according to the article may reel in excess costs and increase user adoption without sacrificing margins — while still passing on the savings to patients. | ||
Revision as of 12:09, 10 April 2024
| How pharma can overcome inflation (with abstract) | |
|---|---|
| Published By | [[Pharma manufacturing]] |
| Publish Date | Sept. 14, 2022 |
| Authors | Cathy Tie |
| Topics | B2B eCommerce in Pharma |
| Statistics | |
| Article Size | words |
| Diagrams | No |
| Downloadable Version | No |
| Reviewers | |
| Page Owner | Nikolay Sidelnikov |
| Summary Author | Nikolay Sidelnikov |
Abstract
The article How pharma can overcome inflation was published by Pharma manufacturing in 2022. It describes the potential effect of D2C business model that according to the article may reel in excess costs and increase user adoption without sacrificing margins — while still passing on the savings to patients.
Full article: How pharma can overcome inflation